Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 3
1980 1
1981 1
1982 1
1983 3
1984 4
1985 2
1986 2
1987 1
1988 2
1989 4
1990 1
1991 4
1992 4
1993 1
1994 4
1995 2
1996 2
1997 4
1998 7
1999 2
2000 5
2001 1
2002 6
2003 3
2004 5
2005 5
2006 3
2007 5
2008 9
2009 11
2010 8
2011 11
2012 4
2013 7
2014 15
2015 18
2016 10
2017 12
2018 11
2019 15
2020 17
2021 12
2022 17
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

259 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20AJ, 5BAuthor
Page 1
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J. Facon T, et al. Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19. Leukemia. 2020. PMID: 31427722 Free PMC article. Clinical Trial.
Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investigated to determine outcomes based on frailty using scores for age, Charlson Comorbidity Index (CCI), and Eastern Cooperative Oncology Group performance status (ECOG …
Patients from the large, phase 3 FIRST trial in newly diagnosed multiple myeloma (NDMM) were retrospectively investigated to determine outco …
Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.
With regard to DRIs, participants in the MAO-B group had mean PDQ-39 mobility scores that were 4.2 points (95% CI, 0.4-7.9 points; P=.03) better than those of the COMT group and EuroQol 5-dimension 3-level (EQ-5D-3L) utility scores that were 0.05 points (95% CI, 0.003-0.09 …
With regard to DRIs, participants in the MAO-B group had mean PDQ-39 mobility scores that were 4.2 points (95% CI, 0.4-7.9 points; P=.03) be …
Chaplains Work in Primary Care.
Snowden A, Telfer I, Vandenhoeck A, Verhoef J, Gibbon A. Snowden A, et al. J Health Care Chaplain. 2023 Apr-Jun;29(2):211-228. doi: 10.1080/08854726.2022.2077555. Epub 2022 Jun 11. J Health Care Chaplain. 2023. PMID: 35695021
Between 2018 and 2019, 143 people used CCL and completed baseline and post-discharge outcome measures. Mean Scottish PROM scores rose from 7.94 ( 3.4) at baseline to 12 ( 3.5) post discharge, a statistically and clinically significant rise of 4.06 (95% CI, 3-5.12), t(50) = …
Between 2018 and 2019, 143 people used CCL and completed baseline and post-discharge outcome measures. Mean Scottish PROM scores rose
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
PD Med Collaborative Group; Gray R, Ives N, Rick C, Patel S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE. PD Med Collaborative Group, et al. Lancet. 2014 Sep 27;384(9949):1196-205. doi: 10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Lancet. 2014. PMID: 24928805 Clinical Trial.
PDQ-39 mobility scores were 1.4 points (95% CI 0.0-2.9, p=0.05) better in patients allocated MAOBI than in those allocated dopamine agonists. EQ-5D utility scores averaged 0.03 (95% CI 0.01-0.05; p=0.0002) better with levodopa than with levodopa-sparing therapy; rates of d …
PDQ-39 mobility scores were 1.4 points (95% CI 0.0-2.9, p=0.05) better in patients allocated MAOBI than in those allocated dopamine agonists …
A Review of the Development and Application of Generic Preference-Based Instruments with the Older Population.
Cleland J, Hutchinson C, Khadka J, Milte R, Ratcliffe J. Cleland J, et al. Appl Health Econ Health Policy. 2019 Dec;17(6):781-801. doi: 10.1007/s40258-019-00512-4. Appl Health Econ Health Policy. 2019. PMID: 31512086 Review.
A variety of generic preference-based instruments have been used to measure older people's quality of life, including the Adult Social Care Outcomes Toolkit (ASCOT); Health Utility Index Mark 2 (HUI2); Health Utility Index Mark 3 (HUI3); Short-Form-6 Dimensions (SF-6D); Assessmen …
A variety of generic preference-based instruments have been used to measure older people's quality of life, including the Adult Social Care …
The European Multiple System Atrophy-Study Group (EMSA-SG).
Geser F, Seppi K, Stampfer-Kountchev M, Köllensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlef F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK; EMSA-SG. Geser F, et al. J Neural Transm (Vienna). 2005 Dec;112(12):1677-86. doi: 10.1007/s00702-005-0328-y. Epub 2005 Jul 29. J Neural Transm (Vienna). 2005. PMID: 16049636 Review.
The NHS comprises assessments of basic anthropometric data as well as a range of scales including the UMSARS, Unified Parkinson's Disease Rating Scale (UPDRS), measures of global disability, Red Flag list, MMSE (Mini Mental State Examination), quality of live measures, i.e. EuroQ …
The NHS comprises assessments of basic anthropometric data as well as a range of scales including the UMSARS, Unified Parkinson's Disease Ra …
Psychometric properties of the PROMIS Preference score (PROPr) in patients with rheumatological and psychosomatic conditions.
Klapproth CP, Fischer F, Merbach M, Rose M, Obbarius A. Klapproth CP, et al. BMC Rheumatol. 2022 Mar 7;6(1):15. doi: 10.1186/s41927-022-00245-3. BMC Rheumatol. 2022. PMID: 35249554 Free PMC article.
The aim of this study was to validate the PROPr in a German inpatient sample and to compare it to the EQ-5D. METHODS: We collected PROPr and EQ-5D-5L data from 141 patients undergoing inpatient treatment in the rheumatology and psychosomatic departments. ...While th …
The aim of this study was to validate the PROPr in a German inpatient sample and to compare it to the EQ-5D. METHODS: We collected PR …
Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals.
Rose M, Rice S, Craig D. Rose M, et al. Pharmacoecon Open. 2018 Jun;2(2):97-107. doi: 10.1007/s41669-017-0040-5. Pharmacoecon Open. 2018. PMID: 29623616 Free PMC article. Review.
Since 2004, National Institute for Health and Care Excellence (NICE) methodological guidance for technology appraisals has emphasised a strong preference for using the validated EuroQol 5-Dimensions (EQ-5D) quality-of-life instrument, measuring patient health status from p …
Since 2004, National Institute for Health and Care Excellence (NICE) methodological guidance for technology appraisals has emphasised a stro …
259 results